NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid-and distal duodenum?
| Autor: | R. Weberg, Lars Aabakken, L. Viksmoen, S. Larsen, M. Osnes, B. A. Bjørnbeth |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Duodenum Stomach Diseases Placebo Gastroenterology Endoscopy Gastrointestinal Random Allocation Double-Blind Method Internal medicine Duodenal bulb Healthy volunteers medicine Humans Pharmacology (medical) Duodenal Diseases Edetic Acid Hepatology business.industry Stomach Anti-Inflammatory Agents Non-Steroidal Famotidine Chromium Radioisotopes Treatment period medicine.anatomical_structure business medicine.drug |
| Zdroj: | Alimentary Pharmacology & Therapeutics. 4:295-303 |
| ISSN: | 1365-2036 0269-2813 |
| DOI: | 10.1111/j.1365-2036.1990.tb00474.x |
| Popis: | SUMMARY Eighteen healthy volunteers were included in a cross-over, double-blind study where 500 mg naproxen b.d. was given for 1 week with 20 mg famotidine b.d., 40 mg nocte or placebo. Endoscopic evaluation of the gastroduodenal mucosa was performed before and after each treatment period, with separate evaluation of the mid- and distal duodenum. 51Cr-EDTA-permeability tests were done to study effects on the mid- and distal gut, and, in addition, symptom registration was performed. The mucosal damage was significant in all treatment periods, and a statistically significant reduction was seen with 20 mg famotidine b.d. for erosive lesions in the stomach/duodenal bulb region as well as for the sum of damage score in the mid- and distal duodenum. The reduction was considerable in a few subjects with extensive duodenal damage. The reduction was considerable in a few subjects with extensive duodenal damage. Intestinal permeation increased significantly in all periods, and was not reduced by famotidine. Symptoms were modest and equal in all periods. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text